“Single-cell antigen-specific activation landscape of CD19 CAR T cell infusion product predicts clinical response and relapse in patients with ALL”

Rong Fan, PhD
Professor of Biomedical Engineering, Yale School of Medicine

Tuesday, February 9, 2021 from 4-5 PM

https://yale.zoom.us/j/91915900534?pwd=REx1Lyt3QzVrcDBhKzJ6blpZa0oxZz09
Password: HTI
Meeting ID: 919 1590 0534
(Or by telephone: 203-432-9666)

CME credit: Text 22205 to 203-442-9435

Host: Dr. Jordan Pober
Course Directors: Dr. Carrie Lucas and Dr. Ellen Foxman

There is no corporate support for this activity. This activity is not supported by any educational grants.

This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
The target audience for the HTI Seminar Series comprises attending faculty, clinical and basic scientists, community physicians, nurses, residents, fellows, and students.

NEEDS ASSESSMENT
The HTI Seminar Series seeks to review the scientific basis for choice of immunologically related therapeutic targets in various diseases, including organ-specific and systemic autoimmunity, allergy, transplant rejection, cancer, and infectious diseases. The goal is to help understand the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice and review the data on the different therapeutic approaches in different specialties.

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
1. Understand the basics of single-cell sequencing techniques
2. Understand the mechanism of CD19-targeting CAR-T therapy
3. Learn the progress in treating Acute Lymphocytic Leukemia

FACULTY DISCLOSURES
Rong Fan: Received equity/salary/options from IsoPlexis, Singleron Biotechnologies, AtlasXomics, and Bio-Techne
Carrie Lucas: None
Ellen Foxman: None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.